<SEC-DOCUMENT>0001144204-19-047076.txt : 20191003
<SEC-HEADER>0001144204-19-047076.hdr.sgml : 20191003
<ACCEPTANCE-DATETIME>20191003063147
ACCESSION NUMBER:		0001144204-19-047076
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191001
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191003
DATE AS OF CHANGE:		20191003

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		191134383

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv530575_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
October 1, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Applied DNA Sciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or other jurisdiction<BR>
of incorporation)</P></TD>
    <TD STYLE="width: 34%; text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 33%; text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(IRS Employer<BR>
Identification
No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>50 Health Sciences Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Stony Brook, New York 11790</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices;
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>631-240-8800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white; color: #231F20">Securities
registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #222222">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; font: bold 10pt Times New Roman, Times, Serif; color: #231F20; text-align: center; border-bottom: Black 1pt solid">Title of each class</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; color: #231F20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 20%; font: bold 10pt Times New Roman, Times, Serif; color: #231F20; text-align: center; border-bottom: Black 1pt solid">Trading
    Symbol(s)</TD><TD STYLE="width: 1%; font: bold 10pt Times New Roman, Times, Serif; color: #231F20; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 44%; font: bold 10pt Times New Roman, Times, Serif; color: #231F20; text-align: center; border-bottom: Black 1pt solid">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock, $0.001 par value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">APDN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">The NASDAQ Capital Market</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: #222222; text-align: left">Warrants to purchase Common Stock</TD><TD STYLE="font-size: 10pt; color: #222222">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #222222">APDNW</TD><TD STYLE="font-size: 10pt; color: #222222">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; color: #222222; text-align: left">The NASDAQ Capital Market</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter). Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Item 7.01 Regulation FD Disclosure.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On October 1, 2019,
Applied DNA Sciences, Inc. (the &ldquo;<B>Company</B>&rdquo;) received written notice from the Nasdaq Hearings Panel of The Nasdaq
Stock Market LLC (the &ldquo;<B>Panel</B>&rdquo;) indicating that the Panel has granted the Company&rsquo;s request for the continued
listing of the Company&rsquo;s securities on The Nasdaq Capital Market (&ldquo;<B>Nasdaq</B>&rdquo;), subject to the Company evidencing
compliance on or before December 31, 2019 with both the minimum $1.00 bid price and that it has at least $2.5 million in stockholders&rsquo;
equity, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively. During this time, the Company&rsquo;s securities
will remain listed and trading on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, on October
3, 2019, the Company issued a press release with regard to the written notice it received from the Panel. The press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The information related
to the press release furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo; for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), or otherwise
subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Item 9.01. Financial Statements and Exhibits.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(<I>d)</I></TD><TD STYLE="text-align: justify"><I>Exhibits</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt"><A HREF="tv530575_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="text-align: justify; padding-top: 3pt"><A HREF="tv530575_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Applied DNA Sciences, Inc. dated October 3, 2019.</FONT></A></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 39.65pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 3, 2019</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPLIED DNA SCIENCES, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 37%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;James&nbsp;A.&nbsp;Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James A. Hayward</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.9in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3pt"><A HREF="tv530575_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="text-align: justify; padding-top: 3pt"><A HREF="tv530575_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Applied DNA Sciences, Inc. dated October 3, 2019.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv530575_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="text-transform: uppercase"><B>Exhibit</B></FONT><B> 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Applied DNA Receives
Extension from Nasdaq</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><B>STONY BROOK, N.Y., October 3, 2019</B>&nbsp;&ndash;&nbsp;Applied
DNA Sciences, Inc.&nbsp;(NASDAQ: APDN) (&ldquo;Applied DNA&rdquo;) (&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the
 &ldquo;Company&rdquo;), a leader in large-scale PCR-based DNA manufacturing, today announced that the Nasdaq Hearings Panel (the
 &ldquo;Panel&rdquo;) , has granted Applied DNA&rsquo;s request for an extension through December 31, 2019, to comply with all
applicable criteria for continued listing of the Company&rsquo;s securities on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;),
including the minimum $1.00 bid price and $2.5 million stockholders&rsquo; equity requirements. During the extension, Applied
DNA&rsquo;s securities will remain listed on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&ldquo;We are appreciative of the Nasdaq Hearings Panel&rsquo;s
decision to grant us our requested extension to evidence compliance with all applicable requirements for continued listing on
Nasdaq. The management team and Board of Directors place the highest priority on our continued listing, and we want to assure
all stakeholders that we continue to work diligently on executing on our compliance plan,&rdquo; stated Dr. James A. Hayward,
president and CEO of Applied DNA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The Company is diligently working to comply with the minimum
$1.00 bid price and $2.5 million stockholders&rsquo; equity requirements; however, there can be no assurance that the Company
will be able to regain compliance with the applicable listing criteria within the period granted by the Panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><B>About Applied DNA Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic
drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white">Applied DNA makes life real and safe
by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply
chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Visit adnas.com for more information. Follow us on Twitter
and LinkedIn. Join our mailing list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white">Common stock listed on NASDAQ under
the symbol APDN, and warrants are listed under the symbol APDNW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">The statements made by Applied DNA in this press release may
be &ldquo;forward-looking&rdquo; in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements describe Applied DNA&rsquo;s future plans, projections, strategies and expectations, and are based on assumptions and
involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ
materially from those projected due to its ability to continue as a going concern, its history of net losses, limited financial
resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting
notices received, and various other factors detailed from time to time in Applied DNA&rsquo;s SEC reports and filings, including
our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on
February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at&nbsp;www.sec.gov.
Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><B>investor contact:&nbsp;</B>Sanjay
M. Hurry, LHA Investor Relations<B>,&nbsp;</B>212-838-3777,&nbsp;shurry@lhai.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><B>web:&nbsp;</B>www.adnas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><B>twitter:&nbsp;</B>@APDN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W U(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH ***,_P"?H<4 %%%% !1110 44A(&<GH,_P _\#2;U]STX )(SCT^M)RB
MMVEZM+\[!_77_(=12%@.?Y>W7Z=>] .1GL1G\*+J]KJ_:^OW!?\ K^M/Q%HI
MNX9QU/H/\^XS3AS^OZ'%":=[-.V]FG;U ****8!1110 4444 %%%% !1110
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M:_[4UJU>R_<_UL_+GGQ)F4;6^K:NW^[I]6MO:WZ-[[6;WU^H#\=?""G'V#Q
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M62>XE\36F@:A%J.@I>2WUS=7T46I>'-0N-+NM4U@Z'J6FV>J7MA<>F?MA_\
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MW1N=$T>UO=1U%!&+W4+:Q@6$7'Y0>#OV3OVB_P#@IE\9=7\4?L>_L/:3\*?
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M_(WZQG&<G.-"/)[\8Z8 [_V3X'H/R%&!Z#\A6B^E;XNI66)X9Z?\TU0MI?\
MZF'G_P ,0_HN>%K=W2XBOKMG]5;JW_0O/XRG_P"""O[;3$G^W?@F!C!'_"7Z
MQ@C&>V@@\Y/]*IM_P0/_ &WCD_V[\$QG(!/B_6,?B!H.>1UX/:O[0<#T'Y"C
M ]!^0K1?2R\8%>V*X7UZ/AG#OR_Z&']=S.7T6/"R5[T^)-?^J@J__._KU/XL
M&_X(#_MPEOEUWX(GG@?\)?JXX['/]@D9QVR>N*J/_P $ /VY&;(UWX'J#GC_
M (3'6<XW9SD: 1CKC&3UXSBO[6L#T'Y"C ]!^0K1?2X\8U?_ &GA5WTUX7P^
MW;_D8KN]?GO9K-_12\*&[NGQ+\N(:J\_^A=W_P"'/XX[3_@W7_:HEM;:6Z^-
M?P1M+F6WADN+1;;QC<K:SO&K36ZW"::B3B"0M&)E1%E"[U50P *_L<P/0?D*
M*XW]*_QN;;7$.41NV^6/"V2\L;MOEC=2?+&]E>4G9*[;NWVKZ+G@\DD\DS63
M22<GQ'FUY-))R=DE>33;LDKMV25DEHHHK^<3^APHHHH **** "BBB@ HHHH
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
